1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Proton Pump

Proton Pump

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-105220
    WY-47766
    Inhibitor
    WY-47766(OST-766) is aproton pumpinhibitor.
    WY-47766
  • HY-17507BR
    Pantoprazole sodium hydrate (Standard)
    Inhibitor
    Pantoprazole (sodium hydrate) (Standard) is the analytical standard of Pantoprazole (sodium hydrate). This product is intended for research and analytical applications. Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole sodium hydrate (Standard)
  • HY-W008614R
    Lansoprazole sulfone (Standard)
    Inhibitor
    Lansoprazole sulfone (Standard) is the analytical standard of Lansoprazole sulfone. This product is intended for research and analytical applications. Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease.
    Lansoprazole sulfone (Standard)
  • HY-17023R
    Esomeprazole sodium (Standard)
    Inhibitor
    Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole sodium (Standard)
  • HY-100413
    CS-526
    Antagonist
    CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H+,K+-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease.
    CS-526
  • HY-B0656AR
    Rabeprazole sodium (Standard)
    Inhibitor
    Rabeprazole (sodium) (Standard) is the analytical standard of Rabeprazole (sodium). This product is intended for research and analytical applications. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux.
    Rabeprazole sodium (Standard)
  • HY-B0656AS1
    Rabeprazole-d3 sodium
    Inhibitor
    Rabeprazole-d3 sodium the deuterium labeled Rabeprazole sodium (HY-B0656A). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux.
    Rabeprazole-d<sub>3</sub> sodium
  • HY-17021S
    Esomeprazole-d3 sodium
    Inhibitor
    Esomeprazole-d3 (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole-d<sub>3</sub> sodium
  • HY-N14423
    Concanamycin D
    Inhibitor
    Concanamycin D is a lysosomal acidification inhibitor with an IC50 value of 0.085 nM.
    Concanamycin D
  • HY-W703279
    (R)-(+)-Pantoprazole sodium
    Inhibitor
    (R)-(+)-Pantoprazole ((R)-(+)-BY1023) sodium is a proton pump inhibitor that can be used for the study of gastroesophageal reflux disease.
    (R)-(+)-Pantoprazole sodium
  • HY-W739793
    Pantoprazole-d8 sodium
    Pantoprazole-d8 (BY1023-d8) sodium is a deuterium labeled Pantoprazole (HY-17507). Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole-d<sub>8</sub> sodium
  • HY-117110
    Arginylproline
    Arginylproline (H-Arg-Pro-OH) is a dipeptide consisted of arginine and proline. Arginylproline reduces intracellular triglyceride (TG) levels stimulated by Oleic acid (HY-N1446), through the peptide transporter 1 (PepT1) pathway.
    Arginylproline
  • HY-118115
    Pyrabactin
    Pyrabactin is a seed-selective abscisic acid (ABA) agonist that acts through Pyrabactin Resistance 1 (PYR1) and PYL1. Pyrabactin is used as a synthetic plant growth inhibitor.
    Pyrabactin
  • HY-W008614S1
    Lansoprazole sulfone-13C6
    Inhibitor
    Lansoprazole sulfone-13C6 (AG-1813-13C6) is 13C labeled Lansoprazole sulfone. Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease.
    Lansoprazole sulfone-<sup>13</sup>C<sub>6</sub>
  • HY-B2145R
    Ilaprazole sodium (Standard)
    Inhibitor
    Ilaprazole (sodium) (Standard) is the analytical standard of Ilaprazole (sodium). This product is intended for research and analytical applications. Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.
    Ilaprazole sodium (Standard)
  • HY-17021A
    Esomeprazole magnesium salt
    Inhibitor
    Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole magnesium salt
  • HY-17507S2
    Pantoprazole-d8
    Inhibitor
    Pantoprazole-d8 (BY1023-d8) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole-d<sub>8</sub>
  • HY-B1246R
    Thonzonium bromide (Standard)
    Inhibitor
    Thonzonium (bromide) (Standard) is the analytical standard of Thonzonium (bromide). This product is intended for research and analytical applications. Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM).
    Thonzonium bromide (Standard)
  • HY-B0113S5
    Omeprazole-d6
    Inhibitor
    Omeprazole-d6 (H 16868-d6) is deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    Omeprazole-d<sub>6</sub>
  • HY-118367
    A 80915A
    Inhibitor
    A 80915A is a seminaphthoquinone produced by Streptomyces and is a potent inhibitor of Na+/K+ ATPase involved in gastric acid secretion.
    A 80915A
Cat. No. Product Name / Synonyms Application Reactivity